Navigation Links
Researchers Studying Novel Therapy For Prostate Cancer

A team of University of Iowa Health Care researchers has launched an important clinical trial of a novel therapeutic that may eventually lead to new treatments for men// diagnosed with prostate cancer.

The Ad5-TRAIL gene therapy for prostate cancer research trial is a Phase I study designed to test the optimal dosage at which the therapeutic agent can safely be given to patients.

The clinical study is being co-led by Thomas Griffith, Ph.D., an associate professor in the UI Department of Urology, and Richard Williams, M.D., the Rubin H. Flocks Chair in Urology and professor and head of the UI Department of Urology.

"This is the first use of this type of anti-cancer agent which was developed at the University of Iowa. This new gene therapy may help us successfully manage patients with high-risk prostate cancer," Griffith said. "Ideally, we hope to be able to say at the conclusion of this trial that this novel agent is safe and performs as intended by causing the death of prostate tumor cells with no harm to normal cells. However, being at the initial stages of the trial, it is premature to make any claims until the data is analyzed."

Researchers injected the investigational therapeutic into the cancerous prostates of three patients. Then, following a 10-day waiting period, surgeons removed the prostates and are evaluating the results.

"The preliminary results appear promising," Williams said. "The patients have tolerated the treatment without any serious side effects, which we hope will permit us to proceed with the research process."

Investigators plan to enroll up to 12 additional participants in the Phase I segment of the study.

"While the vaccine is not intended to be curative at this stage, the role of the research participants is critically important to what is truly a team effort. Without the involvement of our patients, we could not succeed," said Timothy Ratliff, Ph.D., the An derson-Hebbeln Professor of Urology, and co-investigator in the study.

To create the vaccine, the team used a virus that causes the common cold, but which has been engineered to be non-replicative in humans. The disabled virus, known as an adenovirus, can then be used as a vector, or carrier, of other genes that researchers insert into the virus.

The UI researchers say it will take several years before the treatment could be approved and come into general use, even if it is shown to be effective.

Prostate cancer is the third-leading cause of death among men in the United States. African-American males are at a higher risk for the disease than other men.

Source-Newswise
'"/>




Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Researchers trick Alzheimers Enzyme
4. Researchers find new HIV hiding place
5. New Hair in 15 Days Could Now Be A Possibility Say Researchers
6. Researchers developed world’s smallest toothbrus
7. Researchers discover receptor cells that can cause epilepsy
8. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
9. Researchers reversed the process of memory loss
10. Researchers Identify Key Gene That May Help Brain Treatment
11. Researchers Discover Protein That Causes Malaria
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... ... ... The Dream Builders Project, a 501(c)3 nonprofit organization based in Los Angeles, ... Mexico on Saturday, May 21st. The volunteers took the children out for the day ... 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day in the ...
(Date:5/24/2016)... ... 2016 , ... Global Lyme Alliance (GLA), a leading nonprofit ... has named Scott Santarella as its new CEO. , Santarella is former ... San Francisco, where he successfully helped to grow the organization from a regional ...
(Date:5/24/2016)... ... ... PhysicianOne Urgent Care, advocators in helping their patients lead the healthiest lives possible, updates ... spring. , The official tick season kicks off in May across the states ... themselves to their prey while they feed off their blood. Like other similar biting ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications ... multiplex immunoassays are widely used for cell and protein analysis. Keeping updated on ... quality and efficiency in these areas. , LabRoots introduces a new complementary ...
(Date:5/23/2016)... ... May 23, 2016 , ... On the occasion of his 25th Anniversary of ... weight loss process: , New patients have a consultation and evaluation (done by Dr. ... evaluated. , Body Composition Analysis, There are 15 things that each patient gets checked ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... -- Global Paclitaxel Market 2016 Industry Research ... and the Paclitaxel analysis in this study is supported ... its players. This is the latest Paclitaxel ... current state of the industry while providing a basic ... industry chain structure. The Paclitaxel market analysis is provided ...
(Date:5/23/2016)... , May 23, 2016 The World Health ... PrePex device to include adolescents aged 13 years, and ... can be offered for adult and adolescent males in the ... . PrePex was the first male circumcision device to ... MedTech,s CEO, Eddy Horowitz said: " The ...
(Date:5/23/2016)... May 23, 2016   Purdue Pharma L.P. ... an agreement with Egalet Corporation and Acura Pharmaceuticals, ... part of the agreement the companies will exchange ... all three companies to develop and sell several ... "This agreement reflects the commitment of Purdue Pharma ...
Breaking Medicine Technology: